Automation and artificial intelligence (AI) are changing the nature of work. Together, automation and miniaturization are needed in development and production, to speed-up prototype development and decrease time-to-market and stay competitive in a global world. The credo ‘Automation + Miniaturization = Acceleration’ is successfully applied in many technologies and research areas, however not in synthetic chemistry.
We are developing a technology platform that aims to autonomously discover and optimize early drug candidates. We use methods of automated high throughput nano synthesis, and screening controlled by artificial intelligence. For this we are collating with leading European synchrotrons to determine ligand receptor interactions in a high throughput mode.